🇺🇸 FDA

Intelligence · Clinical Pipeline

HOFFMANN-LA ROCHE Pipeline

All ClinicalTrials.gov programs at HOFFMANN-LA ROCHE — phase, modality, and trial IDs.

Programs
286

Quick answer

HOFFMANN-LA ROCHE has 286 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.

  1. An Open-Label, Multi-Center, Phase Ib/II Study of Glofitamab and Atezolizumab or Polatuzumab Vedotin (Plus A Single Pretreatment Dose of Obinutuzumab) in Adult Patients with Relapsed/Refractory B-Cell Non-Hodgkin’s Lymphoma

    Hoffmann-La Roche

    Relapsed/refractory (r/r) B-cell Non-Hodgkin’s Lymphoma (NHL)

    phase 2 other active

    1 trial

  2. Atezolizumab

    Hoffmann-La Roche

    Advanced Liver Cancers

    phase 2 small molecule active

    1 trial

  3. Avastin 25 mg/ml concentrate for solution for infusion., Lynparza 150 mg film-coated tablets, Cotellic 20 mg film-coated tablets, Ipatasertib, Cotellic, Cotellic, INAVOLISIB, Sindaxel 6 mg/ml concentrat pentru soluţie perfuzabilă, Verzenios 50 mg film-coated tablets, Cotellic, Lynparza 100 mg film-coated tablets, Kadcyla 160 mg powder for concentrate for solution for infusion., LETRO-cell® 2,5 mg Filmtabletten, INAVOLISIB, Verzenios 100 mg film-coated tablets, INAVOLISIB, Lynparza 150 mg film-coated tablets

    Hoffmann-La Roche

    Persistent or Recurrent Rare Epithelial Ovarian Tumors

    phase 2 small molecule active

    1 trial

  4. Avastin 25 mg/ml concentrate for solution for infusion., Tecentriq, Docetaxel Accord 80 mg/4 ml concentrate for solution for infusion, Camonsertib, Trajenta 5 mg film-coated tablets

    Hoffmann-La Roche

    Metastatic non-small cell lung cancer (NSCLC)

    phase 2 small molecule active

    1 trial

  5. BCG-MEDAC, poudre et solvant pour suspension intravésicale, PD1IL2v iMAb

    Hoffmann-La Roche

    BCG-Unresponsive High-Risk Non-Muscle Invasive Bladder Cancer (NMIBC)

    phase 2 small molecule active

    1 trial

  6. Budenofalk 3mg magensaftresistente Hartkapseln, ALIMTA 100 mg powder for concentrate for solution for infusion, KEYTRUDA 25 mg/mL concentrate for solution for infusion., CISPLATINE ACCORD 1 mg/ml, solution à diluer pour perfusion, Carboplatin-GRY® 10 mg/ml Konzentrat zur Herstellung einer Infusionslösung, Cisplatin NeoCorp 1 mg/ml - Konzentrat zur Herstellung einer Infusionslösung, Pemetrexed Accord 25 mg/ml concentrate for solution for infusion, Cisplatin Teva® 1 mg/ml Konzentrat zur Herstellung einer Infu

    Hoffmann-La Roche

    Untreated Advanced or Metastatic Non-Small Cell Lung Cancer

    phase 2 small molecule active

    1 trial

  7. Carboplatin Kabi 10 mg/ml Konzentrat zur Herstellung einer Infusionslösung, Cisplatin Hikma 1 mg/ml Konzentrat zur Herstellung einer Infusionslösung, CARBO-cell® 10 mg/ml Infusionslösung, Konzentrat zur Herstellung einer Infusionslösung, Alectinib (Alecensa), Pemetrexed Fresenius Kabi 25 mg/ml concentrate for solution for infusion, Cisplatin NeoCorp 1 mg/ml - Konzentrat zur Herstellung einer Infusionslösung, Pemetrexed Accord 25 mg/ml concentrate for solution for infusion, Pemetrexed Pfizer 25 mg/ml concent

    Hoffmann-La Roche

    Resectable Stage I-III Non-Small Cell Lung Cancer (NSCLC)

    phase 2 small molecule active

    1 trial

  8. Cetuximab

    Hoffmann-La Roche

    Colorectal Cancer

    phase 2 small molecule completed

    1 trial

  9. Cevostamab, RoActemra 20 mg/mL concentrate for solution for infusion

    Hoffmann-La Roche

    Relapsed/Refractory Multiple Myeloma

    phase 2 small molecule active

    1 trial

  10. Cobimetinib

    Hoffmann-La Roche

    Solid Tumors

    phase 2 small molecule completed

    1 trial

  11. Columvi 10 mg concentrate for solution for infusion, Glofitamab, Gazyvaro 1,000 mg concentrate for solution for infusion., RoActemra 20 mg/mL concentrate for solution for infusion

    Hoffmann-La Roche

    Relapsed/refractory B-cell non-Hodgkin’s lymphoma (r/r NHL)

    phase 2 small molecule active

    1 trial

  12. Copegus

    Hoffmann-La Roche

    Hepatitis C, Chronic

    phase 2 small molecule completed

    1 trial

  13. Crovalimab, Crovalimab, Crovalimab Placebo F01-01, Crovalimab

    Hoffmann-La Roche

    Paroxysmal nocturnal hemoglobinuria (PNH)

    phase 2 small molecule active

    1 trial

  14. DEXAMETHASONE , PEGFILGRASTIM , Mosunetuzumab, DIPHENHYDRAMINE , RASBURICASE , Polivy 140 mg powder for concentrate for solution for infusion., Mosunetuzumab, RoActemra 20 mg/mL concentrate for solution for infusion, Mosunetuzumab, Mosunetuzumab, PREDNISONE , FLUDEOXYGLUCOSE (18F) , METHYLPREDNISOLONE, MabThera 500 mg concentrate for solution for infusion, PARACETAMOL, ALLOPURINOL

    Hoffmann-La Roche

    B-cell non-Hodgkin lymphoma (NHL)

    phase 2 small molecule active

    1 trial

  15. Delandistrogene moxeparvovec-rokl

    Hoffmann-La Roche

    Duchenne Muscular Dystrophy

    phase 2 small molecule active

    1 trial

  16. Diphenhydramine Hydrochloride Tablets 50 mg, Paracetamol 500mg Tablets, Ocrevus 300 mg concentrate for solution for infusion, Methylprednisolone 500 mg powder and solvent for solution for injection/infusion, Ocrevus 300 mg concentrate for solution for infusion

    Hoffmann-La Roche

    Relapsing-Remitting Multiple Sclerosis (RRMS)

    phase 2 small molecule active

    1 trial

  17. Entrectinib

    Hoffmann-La Roche

    Breast Cancer

    phase 2 small molecule active

    1 trial

  18. Entrectinib

    Hoffmann-La Roche

    Solid Tumors

    phase 2 small molecule active

    1 trial

  19. Erlotinib

    Hoffmann-La Roche

    Non-Small Cell Lung Cancer

    phase 2 small molecule completed

    1 trial

  20. Erlotinib

    Hoffmann-La Roche

    Pancreatic Cancer

    phase 2 small molecule completed

    1 trial

  21. Gazyvaro 1,000 mg concentrate for solution for infusion., CellCept 1 g/5 ml powder for oral suspension, Gazyvaro Placebo, Myfenax 500 mg film-coated tablets

    Hoffmann-La Roche

    Lupus Nephritis (LN)

    phase 2 small molecule active

    1 trial

  22. Giredestrant

    Hoffmann-La Roche

    Estrogen Receptor-Positive, HER2-Negative, Locally Advanced or Metastatic Breast Cancer

    phase 2 small molecule active

    1 trial

  23. Giredestrant

    Hoffmann-La Roche

    Early Breast Cancer

    phase 2 small molecule completed

    1 trial

  24. IFOSFAMIDE , MabThera 500 mg concentrate for solution for infusion, ETOPOSIDE , Gazyvaro 1,000 mg concentrate for solution for infusion., CD20 CD3 TCB, RoActemra 20 mg/mL concentrate for solution for infusion, CARBOPLATIN

    Hoffmann-La Roche

    CD20 positive B-Cell Non-Hodgkin Lymphoma (NHL)

    phase 2 small molecule active

    1 trial

  25. INAVOLISIB, DOCETAXEL, INAVOLISIB, ENZALUTAMIDE, ENZALUTAMIDE, ABIRATERONE

    Hoffmann-La Roche

    Metastatic Castration-Resistant Prostate Cancer

    phase 2 small molecule active

    1 trial

  26. INAVOLISIB, FULVESTRANT, INAVOLISIB

    Hoffmann-La Roche

    Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha gene (PIK3CA)-Mutated, hormone receptor-positive (HR-Positive), human epidermal growth factor receptor 2 (HER2)-Negative Locally Advanced or Metastatic Breast Cancer

    phase 2 small molecule active

    1 trial

  27. INAVOLISIB, RIBOCICLIB, INAVOLISIB, RIBOCICLIB, Inavolisib placebo, FULVESTRANT

    Hoffmann-La Roche

    Endocrine-Resistant Hormone-Receptor-Positive, HER2-Negative Advanced Breast Cancer with Chromosome 8p Loss and Without PIK3CA Mutation

    phase 2 small molecule active

    1 trial

  28. INAVOLISIB, RO 743-5846/F04, RO7223619, INAVOLISIB, RO 743-5846/F07, Ipatasertib, Rozlytrek 200 mg hard capsules, Alecensa 150 mg hard capsules, Rozlytrek 100 mg hard capsules, Tecentriq 1 200 mg concentrate for solution for infusion, INAVOLISIB, Rozlytrek, Ipatasertib, Camonsertib, INAVOLISIB, RO 749-9790/F02-02

    Hoffmann-La Roche

    Solid tumors

    phase 2 small molecule active

    1 trial

  29. Iberdomide, Iberdomide, Cevostamab, Iberdomide, Revlimid 10 mg hard capsules, RoActemra 20 mg/mL concentrate for solution for infusion, Iberdomide, Revlimid 5 mg hard capsules

    Hoffmann-La Roche

    Multiple Myeloma (MM)

    phase 2 small molecule active

    1 trial

  30. Idasanutlin

    Hoffmann-La Roche

    Follicular Lymphoma

    phase 2 small molecule terminated

    1 trial

  31. Kadcyla 160 mg powder for concentrate for solution for infusion., Tecentriq 1,200 mg concentrate for solution for infusion, Perjeta 420 mg concentrate for solution for infusion

    Hoffmann-La Roche

    Metastatic Cancer

    phase 2 small molecule active

    1 trial

  32. LETROZOLE ACCORD HEALTHCARE 2,5 mg, comprimé pelliculé, Kisqali 200 mg film-coated tablets, RIBOCICLIB, INAVOLISIB, RIBOCICLIB, LETROZOLE, INAVOLISIB, LETROZOLE, Letrozol STADA® 2,5 mg Filmtabletten

    Hoffmann-La Roche

    Early-Stage, PIK3CA-Mutated Breast Cancer (BC)

    phase 2 small molecule active

    1 trial

  33. Mosunetuzumab

    Hoffmann-La Roche

    Systemic Lupus Erythematosus (SLE) With or Without Active Lupus Nephritis (LN)

    phase 2 small molecule active

    1 trial

  34. Mosunetuzumab, Mosunetuzumab, Revlimid 5 mg hard capsules, Revlimid 10 mg hard capsules, Mosunetuzumab, Mosunetuzumab, Mosunetuzumab, RoActemra 20 mg/mL concentrate for solution for infusion

    Hoffmann-La Roche

    Follicular Lymphoma (FL)

    phase 2 small molecule active

    1 trial

  35. Ocrelizumab

    Hoffmann-La Roche

    Rheumatoid Arthritis

    phase 2 small molecule terminated

    1 trial

  36. Ocrevus, Ocrevus 920 mg solution for injection, Ocrevus, Ocrelizumab

    Hoffmann-La Roche

    Multiple Sclerosis (MS)

    phase 2 small molecule active

    1 trial

  37. P38 Inhibitor (4) 150mg

    Hoffmann-La Roche

    Rheumatoid Arthritis

    phase 2 small molecule completed

    1 trial

  38. Placebo

    Hoffmann-La Roche

    Diabetes Mellitus Type 2

    phase 2 small molecule completed

    1 trial

  39. Placebo RO7269162, RO7269162, RO7269162, RO7269162, FLORBETABEN (18F), FLUTEMETAMOL (18F)

    Hoffmann-La Roche

    Alzheimer’s Disease

    phase 2 small molecule active

    1 trial

  40. Polivy 30 mg powder for concentrate for solution for infusion., Mosunetuzumab, Mosunetuzumab, RoActemra 20 mg/mL concentrate for solution for infusion, Mosunetuzumab, Mosunetuzumab, Polivy 140 mg powder for concentrate for solution for infusion., Mosunetuzumab, Mosunetuzumab

    Hoffmann-La Roche

    Diffuse Large B-Cell Lymphoma (DLBCL)

    phase 2 small molecule active

    1 trial

  41. RO5024048

    Hoffmann-La Roche

    Hepatitis C, Chronic

    phase 2 small molecule completed

    1 trial

  42. RO7034067

    Hoffmann-La Roche

    Spinal Muscular Atrophy (SMA)

    phase 2 small molecule active

    1 trial

  43. RO7034067, Evrysdi 0.75 mg/mL powder for oral solution

    Hoffmann-La Roche

    Spinal Muscular Atrophy (SMA)

    phase 2 small molecule active

    1 trial

  44. RO7046015, RO7046015

    Hoffmann-La Roche

    Early Idiopathic Parkinson’s disease (PD)

    phase 2 small molecule active

    1 trial

  45. RO7197597

    Hoffmann-La Roche

    Grade 1 Endometrial Cancer

    phase 2 small molecule active

    1 trial

  46. RO7204239, GYM329 Placebo

    Hoffmann-La Roche

    Facioscapulohumeral muscular dystrophy (FSHD)

    phase 2 small molecule active

    1 trial

  47. RO7204239, RO7204239 Placebo, Mounjaro 12.5 mg/dose KwikPen solution for injection in pre-filled pen, Mounjaro 15 mg/dose KwikPen solution for injection in pre-filled pen, Mounjaro 5 mg/dose KwikPen solution for injection in pre-filled pen, Mounjaro 10 mg/dose KwikPen solution for injection in pre-filled pen, Mounjaro 10 mg/dose KwikPen solution for injection in pre-filled pen, Mounjaro 2.5 mg/dose KwikPen solution for injection in pre-filled pen, Mounjaro 7.5 mg/dose KwikPen solution for injection in pre-f

    Hoffmann-La Roche

    Obesity

    phase 2 small molecule active

    1 trial

  48. RO7234292, RO7234292 Placebo

    Hoffmann-La Roche

    Prodromal and Early Manifest Huntington’s Disease

    phase 2 small molecule active

    1 trial

Frequently asked questions

How many pipeline programs does HOFFMANN-LA ROCHE have?

286 published programs are linked to this sponsor in our ClinicalTrials.gov index.

Is this the complete company pipeline?

This hub lists all published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.

Data attribution: Data sources · All pipeline programs

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.